Business Wire

NY-IFF/DUPONT/N&B

9.9.2020 23:17:05 CEST | Business Wire | Press release

Share
IFF & DuPont Announce Pricing of $6.25 Billion Senior Notes Offering by Nutrition & Biosciences, Inc.

Regulatory News:

IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF) and DuPont (NYSE:DD) announced today that Nutrition & Biosciences, Inc. (“N&B”) has priced an offering of $6.25 billion of senior unsecured notes, comprised of the following tranches (collectively, the “Notes”): $300.0 million aggregate principal amount of 0.697% Senior Notes due 2022; $1.0 billion aggregate principal amount of 1.230% Senior Notes due 2025; $1.2 billion aggregate principal amount of 1.832% Senior Notes due 2027; $1.5 billion aggregate principal amount of 2.300% Senior Notes due 2030; $750.0 million aggregate principal amount of 3.268% Senior Notes due 2040; and $1.5 billion aggregate principal amount of 3.468% Senior Notes due 2050.

The Notes are to be issued in a private offering exempt from registration in accordance with Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The sale of the Notes is expected to be completed on or about September 16, 2020, subject to customary closing conditions.

Prior to the intended merger of DuPont Nutrition & Biosciences business with IFF, N&B will make a special cash payment of $7.3 billion to DuPont, which N&B plans to finance with the net proceeds from the offering of the Notes, together with borrowings under its existing Term Loan facilities. Following the payment, N&B will separate from DuPont and merge with a subsidiary of IFF with N&B surviving the merger as a wholly owned subsidiary of IFF. Upon the consummation of the merger, IFF will initially guarantee the Notes and, subsequently, has the option to assume the N&B obligations.

The Notes are being offered only (1) to persons reasonably believed to be qualified institutional buyers in reliance upon Rule 144A under the Securities Act and (2) outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements under the Securities Act or any state securities laws.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves.

About DuPont
DuPont (NYSE:DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food and worker safety.

About DuPont Nutrition & Biosciences
DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities.

Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements regarding closing of the offering described above, use of the related proceeds and the expected combination of N&B and IFF and other statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TwentyTwo Real Estate to Acquire Terhills Resort in Belgium from LRM18.5.2026 15:00:00 CEST | Press release

TwentyTwo Real Estate, an independent European real estate investment and management firm, announces it has agreed to acquire Terhills Resort in Belgium from LRM. The transaction is expected to close on 29 May 2026. Operated by Center Parcs, the premium holiday park spans 63 hectares and comprises 250 waterfront cottages alongside central leisure facilities, set within a unique natural environment at the gateway to Hoge Kempen National Park. Center Parcs will remain the operator of the resort for at least the next 10 years, ensuring continuity for guests and supporting the long-term positioning of the resort as a leading leisure destination in Limburg, one of Flanders’ most distinctive tourism regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513424487/en/ Opened in 2021, Terhills Resort forms part of the broader long-term transformation of the surrounding area into a leading nature, tourism and leisure destination.

Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden18.5.2026 14:30:00 CEST | Press release

The state-of-the-art facility enhances support for complex modalities across all phases of drug developmentKey facts Thermo Fisher opensnew bioanalytical and biomarker laboratory in Gothenburg, Sweden Designed to deliver comprehensive, full-service bioanalytical and biomarker solutions Supports pharmaceutical and biotechnology customers across all phases of drug development Helps customers globally accelerate innovation and bring new therapies to patients faster Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. This new facility expands the company’s global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development. With state-of-the-art instrumentation and Good Laboratory Practice (GLP) capabilities, the laboratory provides rapid, reliable bioanalytical and biomarker servi

HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion18.5.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has received approval from the Taiwan Food and Drug Administration (TFDA) for the Edison® System, representing a significant milestone in the company’s global expansion efforts and continued growth across Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518694013/en/ HistoSonics Edison® Histotripsy System Taiwan is widely recognized as one of the most advanced and strategically important medical device markets in the region, known for its rigorous regulatory standards and highly innovative physician community. The TFDA approval process included a detailed review of the company’s clinical and regulatory submission package and concluded with unanimous agreement from committee members. The approval further reinforces the growing clinical and regulatory momentum behind histotripsy, a non-invasive, non-th

FurtherAI Appoints Tom Bradley to Lead UK and EU Expansion18.5.2026 14:00:00 CEST | Press release

FurtherAI, the AI platform purpose-built for insurance, today announced the appointment of Tom Bradley to lead its UK and EU operations. This marks a significant step in FurtherAI's international expansion, as the company moves to establish a local presence in one of the world's most important insurance markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518611218/en/ FurtherAI Appoints Tom Bradley to lead UK & EU expansion FurtherAI is already working with leading partners in the UK, and Tom's appointment will allow the company to deepen those relationships, build a local team, and serve the rapidly growing demand from carriers, MGAs, and brokers across the Lloyd's market and the wider region. A market moving fast on AI The Lloyd's market and the broader UK and European insurance ecosystem are adopting AI at a pace few would have predicted even twelve months ago. From submission gateways to policy audits to claims, o

Bending Spoons Closes Acquisition of Tractive18.5.2026 13:48:00 CEST | Press release

Technology company Bending Spoons today announced that it has closed the acquisition of Tractive, an Austria-based global leader in location tracking and health monitoring for pets. The definitive acquisition agreement was entered into in March 2026. Michael Hurnaus, Tractive’s CEO and co-founder, said of the acquisition: “Building Tractive into a global leader in pet safety over the past thirteen years has been an extraordinary journey. We set out to give pet owners peace of mind, and grew that mission into a product trusted by millions of people across the world. I'm proud of everything the team has achieved, and excited about how far Tractive will reach under Bending Spoons. Their global platform and technological capabilities will help keep Tractive at the cutting edge, combining our strong European innovation culture with the scale needed to reach even more pet parents around the world.” Luca Ferrari, the Bending Spoons CEO and co-founder, today said: “We’re impressed by what the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye